Pharmaceutical formulations for local application containing low concentrations of benzoyl peroxide in suspension in water and water-miscible organic solvent

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and dermatology, and represents a water-based formulation for local application for treating acne, containing water, a water-miscible organic solvent and benzoyl peroxide, wherein the organic solvent concentration is 1-4 times higher than the benzoyl peroxide concentration in the formulation; the water and organic solvent concentrations are related as at least 7:1, preferentially at least 10:1, more preferentially at least 20:1; the benzoyl peroxide concentration in the formulation makes less than 5.0 wt %, but at least 1.0 wt %.

EFFECT: invention provides the clinical effectiveness with the reduced active agent concentration, as well as reduced irritant action.

27 cl, 4 ex, 3 tbl

 

The technical FIELD

The present invention relates to pharmaceutical compositions for topical application, intended for the treatment of dermatological diseases. In particular, the present invention relates to compositions comprising benzoyl peroxide and optionally containing protivougrevoe connection, such as an antibiotic.

The LEVEL of TECHNOLOGY

Benzoyl peroxide is often used in pharmaceutical compositions for topical application for the treatment of dermatological diseases such as acne, often called acne. Antibiotics for topical use are also used in compositions for topical treatment of dermatological diseases such as acne. Examples of antibiotics used for the local treatment of acne include macrolide antibiotics such as erythromycin, and lenkomecologiya antibiotics such as clindamycin and lincomycin.

The combined products containing benzoyl peroxide and the antibiotic, showed high efficiency protivougrevoe steps compared with compositions containing only benzoyl peroxide or antibiotic. Klein, U.S. patent No. 4497794, describes a combined composition for the treatment of acne containing benzoyl peroxide and erythromycin. The composition obtained as described in Klein '794, sold under t is loveu brand Benzamycin (Benzamycin®) (Dermik Laboratories, Berwyn, PA). The combination of benzoyl peroxide and a group of antibiotics lincomycin, such as clindamycin, described in Klein, U.S. patent No. 5767098, Baroody, U.S. patent No. 5733886, and Stiefel, U.S. patent No. 5466446. The composition obtained as described in Klein '098, sold under the trademark Benzaclin (Benzaclin®) (Dermik Laboratories), and the compositions obtained as described in Stiefel, sold under the trademark Duac (Duac®) (Stiefel Laboratories, Inc., Coral Gables, FL).

One of the problems associated with local therapy compositions containing benzoyl peroxide otdeljnoye in combination with an antibiotic, is a localized irritation at the application site. It was shown that the potential irritation benzoyl peroxide depends on its concentration. Cm. Mills et al., International Journal of Dermatology, 25(10):664-667 (1986) and Lassus, Current Medical Research and Opinion, 7(6):370-373 (1981). Each of the above products contain benzoyl peroxide at a concentration of 5 wt. -%, which is associated with irritation.

Benzoyl peroxide is practically insoluble in water. It was found that the irritation caused by the use of compositions containing benzoyl peroxide due to share peroxybenzoyl held in suspension, while dissolved benzoyl peroxide causes minor skin irritation, or not at all irritating. Cm. Schwarz, U.S. patent No. 7153888; and De Villez, U.S. Patent No. 4923900. Schwarz describing the t of the composition, containing benzoyl peroxide, and benzoyl peroxide in the composition is in solution with an organic solvent. Due to the fact that the dissolution of benzoyl peroxide enhances the destruction of the specified connection, Schwarz indicates that the composition included the antioxidant to stabilize the solution.

The drawback Schwarz composition is that for dissolving benzoyl peroxide requires a high concentration of organic solvent. High concentrations of organic solvents usually irritate the skin, mainly due to the drying action arising due to the increased solubility of the lipids of the skin. In tables 1-3 Schwarz cites numerous examples of compositions containing various organic solvents and benzoyl peroxide. In each of the examples, the concentration of organic solvent is about 10 times, and in most cases, a 15-fold higher concentration of benzoyl peroxide in the composition.

De Villez describes a composition containing benzoyl peroxide, water and miscible with water and evaporating slower water, an organic solvent, which can dissolve the benzoyl peroxide. Before application to the skin, benzoyl peroxide is in the composition in suspension. However, when applied to the skin, the water evaporates from the composition relative activities is but fast compared to organic solvent. Then the benzoyl peroxide composition is dissolved in situ in the organic solvent, resulting after evaporation of the water produces a solution of benzoyl peroxide.

To ensure that the composition according to De Villez transformed from a suspension in a solution, the composition should remain on the skin for sufficient time to ensure that water from the composition has evaporated. During this time, the benzoyl peroxide is in the composition in suspension, and the suspended particles can interact with the skin, causing irritation. Moreover, in the composition according to De Villez, as according to Schwarz, requires a relatively high concentration of organic solvent that may affect the potential irritation to such compositions.

DETAILED description of the INVENTION

It was unexpectedly discovered that essentially the same clinical protivougrevoe effect attained by the use of an aqueous composition for topical application containing 0.5% benzoyl peroxide, is provided by an aqueous composition for topical application containing a suspension of benzoyl peroxide at low concentration in a saturated aqueous solution miscible with water and organic solvent. All concentrations expressed in %, in this application relate to the mass percent (% wt./mass.). Compared to the same composition, with the holding of 5.0% benzoyl peroxide, the composition according to the present invention causes less skin irritation after application without compromising clinical efficacy.

In one implementation of the present invention proposed a pharmaceutical composition for topical application containing water, miscible with water, an organic solvent (the ratio of the concentrations of water and an organic solvent is high) and benzoyl peroxide (at a concentration of benzoyl peroxide in the composition is low). In this application, the term "low concentration" means a concentration of less than 5.0% of the mass, when it comes to concentration of benzoyl peroxide in the composition. Preferably, the pharmaceutical composition is a gel-like composition is water-based. Preferably, the pharmaceutical composition does not contain surface-active substances.

Benzoyl peroxide is represented in the form of a homogeneous suspension. Preferably, the suspended benzoyl peroxide has an average particle size less than 100 microns, more preferably 1-50 μm, most preferably 2.5 to 30 μm. It is necessary that part of benzoyl peroxide was dissolved in the organic solvent, and to a small part of benzoyl peroxide was dissolved in the water. Accordingly, the composition is a saturated solution of benzoyl peroxide and the concentration of dissolve the military benzoyl peroxide above, than when dissolved in water without organic solvent.

In the preferred implementation, but not necessarily, the composition according to the invention contains at least one additional chemical compound, which is effective for the treatment of acne. Protivougrevoe the connection can be suspended or dissolved in the composition. Preferably, protivougrevoe compound is soluble in water, and thus dissolved in the composition. One such preferred protivopravnych compounds is an antibiotic. Preferred are a group of antibiotics of the macrolide, such as erythromycin, azithromycin, clarithromycin, tilmicosin and tylosin, and the group of antibiotics, lincomycin, such as clindamycin and lincomycin. The most preferred antibiotic for use in combination with benzoyl peroxide in the composition according to the present invention is clindamycin, in the form of hydrochloride or clindamycin phosphate clindamycin. Additional protivougrevoe active components that may be included in the composition according to the present invention, as containing an antibiotic and does not contain it include salicylic acid, azelaic acid, Niacinamide, urea, and retinoids such as tretinoin, adapalene, tazarotene.

Additional protivougrevoe connection in case if it is contained in the composition according to the present invention, preferably contained in a concentration that provides a pronounced protivougrevoe effect in the absence of benzoyl peroxide. For example, if clindamycin is included in the composition according to the present invention, the concentration of clindamycin should be achieved preferably at least about 0.5%, most preferably 1%. In the composition according to the present invention can be used, and higher concentrations of clindamycin, such as 2.5% or 5% or above.

The organic solvent in the composition according to the present invention has the following characteristics:

(1) miscible with water

(2) does not enter into chemical reaction with benzoyl peroxide at temperatures from 0 to 40°C,

(3) is a liquid at temperatures from 0 to 40°C,

(4) capable of dissolving benzoyl peroxide at concentrations of at least 0.1 percent at room temperature,

(5) is capable of dispersing benzoyl peroxide to the state of the water-soluble gel in the absence of surfactants.

An example of a preferred organic solvent for the composition according to the present invention is a polyol, also known as the polyhydric alcohol. Typical examples of polyols include glycols and alcohols-sugar. The preferred polyols for having the composition according to the present invention include glycol polyethers, such as etokxidiglicol, and propylene glycol. Preferred miscible with water, the solvent is propylene glycol. The authors of the present invention was determined using HPLC analysis that benzoyl peroxide is soluble in 100% propylene glycol at room temperature at a level of 0.2-0.3% of the mass. The second preferred organic solvent is etokxidiglicol, such as sold under the trade name Transcutol (Transcutol®) (Gattefosse, Saint-Priest, France). Using HPLC analysis, it was determined that the benzoyl peroxide is dissolved in etokxidiglicol at room temperature at a concentration of about 4.9%. Other preferred organic solvent is a glycol, such as PEG 400.

The concentration of organic solvent in the composition should be high enough to provide a stable suspension of benzoyl peroxide in a liquid water-based without the presence of surfactants. The concentration of the organic solvent should be lower than the concentration at which the whole of benzoyl peroxide composition will dissolve after removing all the water from the composition. In General, the concentration of the organic solvent must not exceed the concentration of benzoyl peroxide in the composition of 1-4 times.

In addition, the concentration ratio of water and organic solvent in the composition is supposed to be great, to support the benzoyl peroxide in the state of maximum solubility or close to it state in the residual part, which remains on the skin after application of the composition with subsequent evaporation of water from the composition, thus maximizing thermodynamic activity of benzoyl peroxide in the residual composition on the skin. Thus, the composition according to the present invention it is preferable that the relative concentrations of water and an organic solvent comprised of at least 7:1, for example at least 9:1 or 10:1, preferably at least 12:1, most preferably at least 20:1 to 98:1.

The concentration of benzoyl peroxide in the composition reaches less than 5.0% and is effective for the treatment of the signs and/or symptoms of acne. At concentrations of benzoyl peroxide in the composition according to the present invention, the skin irritation is reduced in comparison with compositions containing 5.0% of benzoyl peroxide. For these reasons, the invention is suitable concentration of benzoyl peroxide from 1.0% to 4.5%. Preferred are concentrations of benzoyl peroxide from 2.0% to 3.5%. The most preferred concentration of benzoyl peroxide is about 2.5%, i.e. between 2.3% and 2.7 per cent.

The composition according to the present invention can be one of many types of structures for local PR the changes, containing water as a main ingredient, such as solutions, gels, creams, sprays and foams. Preferably, but not necessarily that the composition was in the form of water-based gel. Accordingly, the composition according to the present invention may contain a gelling or thickening agent. Any dispersible in water, the gel is suitable for use on epithelial tissue, for example, the skin, and form gels with water-based relatively homogeneous composition suitable for use in compositions according to the present invention. One preferred gel is hydroxypropylcellulose, for example, sold under the trademark KLUCEL® (Hercules Incorporated, Wilmington, DE, USA). Another preferred gel is hydroxyethylcellulose, for example, sold under the trademark NATROSOL® (Hercules Incorporated). Other suitable geleobrazovanie includes carbonylbis polymers, also known as carbomer, for example, sold under the trademark CARBOPOL® 934, 940, 941, 980 and 981 (B.F. Goodrich Co., Akron, OH, USA), ETD 2020™ and ULTREZ® (a Noveon, Inc., Cleveland, OH, USA). Also suitable heleonastes include polyvinyl alcohol, polyethylene oxides, propylene glycol alginates, methylcellulose, hypromellose and natural polymeric resin, such as xanthan gum and carrageenan. The concentration of gelling the connection can vary depending on a number of factors, such as the required degree of stabilization of the suspension of benzoyl peroxide and the desired viscosity of the composition is in the form of a gel.

If necessary, the composition according to the present invention may also contain additional pharmaceutically acceptable molding commonly used in the compositions and well-known specialists in this field of technology. These formative includes, for example, wetting, softeners, stabilizers, pH, preservatives, chelating agents and antioxidants.

The composition according to the present invention can be applied to treat acne by applying a composition to the affected areas of skin, such as on the face, neck, back and chest. The composition according to the invention preferably is applied one or more times a day for a time sufficient to improve the condition of skin. Unexpectedly it was found that the composition according to the present invention, containing 2.5% benzoyl peroxide, has protivougrevoe effect, comparable to that achievable with the application of the composition containing 5.0% of benzoyl peroxide, both compounds also contains the antibiotic clindamycin 1%. Also unexpected is the fact that such an effect was also observed when applying the composition according to the present invention only once a day, while the composition containing 5% benzoyl peroxide, is osili twice a day.

The composition according to the present invention may also be applied for the treatment of acne rosacea. In the treatment of acne rosacea, a composition according to the present invention is applied on the affected areas, preferably one or several times a day for a time sufficient to reduce the signs and symptoms of acne rosacea.

The composition according to the present invention can be manufactured by any method in which the components according to the present invention are combined to obtain the pharmaceutical composition. For example, the suspension of benzoyl peroxide can be obtained by combining water, miscible with water, an organic solvent and benzoyl peroxide. Preferably, the mixture is stirred, for example, by stirring, the dispersion by means of ultrasound, grinding and/or shaking, to obtain a homogeneous suspension of particles of benzoyl peroxide in water and an organic solvent. Additional ingredients, such as geleobrazovanie or other molding can be added either before or after a homogeneous suspension.

If the structure add additional protivougrevoe tool, it can be combined with other components before or after the formation of the suspension of benzoyl peroxide. Another option is getting a separate aqueous solution about evogrip means, such as clindamycin, and the connection of this solution with a suspension of benzoyl peroxide to produce the final composition.

The present invention is described further by the following non-limiting examples.

Example 1 is Illustrative composition according to the present invention

Was obtained pharmaceutical composition according to the present invention, containing the following components, shown in Table 1.

Table 1
COMPONENTWt.%
Benzoyl peroxide2,5
Propylene glycol5,0
The carbopol (Carbopol) 980®1,75
The potassium hydroxide0,5
WaterThe required number to 100 (90,25)

Example 2 is Illustrative composition according to the present invention

Was obtained pharmaceutical composition according to the present invention, containing in addition to benzoyl peroxide protivougrevoe connection with the contents of the following components shown in Table 2.

Table 2
COMPONENTWt.%
Benzoyl peroxide2,5
Propylene glycol5,0
Clindamycin phosphate1,2*
The carbopol (Carbopol) 980®1,75
The potassium hydroxide0,5
WaterThe required number to 100 (89.05)
* equivalent to 1.0% clindamycin

Example 3 - Comparative effectiveness

The gel composition of water-based according to Example 2, containing 2.5% benzoyl peroxide, 5% propylene glycol, 89% water and 1% clindamycin, tested the effectiveness of the treatment of acne lesions in the framework of extensive clinical research involving 399 patients. The composition according to the present invention is named in Part A. Also was prepared with a similar composition in the form of a water-based gel containing 5.0% of benzoyl peroxide, 10% propylene glycol, 82,5% water and 1.0% clindamycin, which also tested the effectiveness of the treatment of acne lesions in the second clinical research is the Finance under very similar conditions. This composition is not a composition according to the present invention, called Part C. the Results were compared with that given in the instructions for medical use of information about the effectiveness of a commercial product in the form of a water-based gel containing 5.0% of benzoyl peroxide and 1% clindamycin, dioctyl sulfosuccinate sodium (surfactant) and water (Benzaclin (BenzaClin® Topical Gel, Dermik Laboratories, Bridgewater, NJ)). This prototype structure called the Composition Sastava a and b did not contain surfactants. The composition was applied only once a day, while Compositions b and C, each of which contains 5.0% of benzoyl peroxide was applied twice daily over a 12-week course of treatment. Testing of Composition And conducted after 12 weeks of use. Data for Compositions b and C obtained after 10 weeks of use.

According to the instructions, subjects had to apply the composition to the face twice a day in case of Formulations b and C, or once a day in case of composition A. After 10 weeks of use of the Compositions b and C and 12 weeks of application of the Composition was determined the average degree of reduction of inflammatory and noninflammatory acne items. The percentage decrease in the number of inflammatory cells (pustules and papules) was calculated by subtracting the total number of inflammatory cells to the end of the study (10 or 12 weeks) from the total the number of inflammatory cells in the initial state, multiplying by 100 and dividing by the total number of inflammatory cells in the initial state. Noninflammatory elements included open comedones and closed comedones; percentage reduction in the number of non-inflammatory elements were calculated in the same way. The results of this study acne are given in Table 3.

Table 3
The composition AndCompositionThe composition of
Number of subjects399481215
Average % reduction in the number of inflammatory cells acne48,859,253,5
Average % reduction in the number of non-inflammatory acne items42,651,036,1

The data in Table 3 show that the effectiveness of the Composition And containing only 2.5% benzoyl peroxide, which is comparable with the efficiency of Trains and C. the results are particularly unexpected in view of the fact that the Composition And inflicted only once a day, BP is me as Compositions b and C were applied twice a day.

Example 4 - Potential irritation

Compositions a and b according to Example 3, each of which contain benzoyl peroxide and 1.0% clindamycin, were tested to determine the comparative potential irritation of these two compounds. The composition according to the present invention contains 2.5% benzoyl peroxide, propylene glycol at a concentration two times higher than the benzoyl peroxide, and water at a concentration of 17.8 times higher than propylene glycol. The composition contains 5.0% of benzoyl peroxide, propylene glycol at a concentration two times higher than the benzoyl peroxide, and water in a concentration of 8.25 times higher concentrations of propylene glycol.

Compositions a and b in the form of gel was applied and pasted separate pieces of tape on the back of 33 healthy subjects three times a week for three weeks. After each deposition was observed within 48 hours on the subject of irritation or inflammation, and determined the degree of irritation by using a standardized evaluation system of annoyance on a scale of severity from 0 (no signs of irritation) to 4 (redness with swelling and the formation of abscesses). Data obtained from this study showed that the use of the Composition according to the present invention reduce the total number of stimuli in comparison with the Composition In 33%.

Further modifications, variations applies the Deposit and use of the invention, described in this application are obvious to experts in the given field of technology. It is assumed that such modifications are included in the above description and the following claims.

1. The composition of the water-based local application on the skin for acne treatment containing water, miscible with water, an organic solvent and benzoyl peroxide, in which the concentration of organic solvent 1-4 times the concentration of benzoyl peroxide in the composition, and the concentration ratio of water and organic solvent in the composition is at least 7:1, preferably at least 10:1, most preferably at least 20:1, and the concentration of benzoyl peroxide in the composition is less than 5.0 wt.%, but at least 1.0 wt.%.

2. The composition of the water-based according to claim 1, characterized in that the concentration of benzoyl peroxide is from 2.0 to 3.5 wt.%.

3. The composition of the water-based according to claim 2, characterized in that the concentration of benzoyl peroxide is about 2.5 wt.%.

4. The composition of the water-based according to claim 1, characterized in that the organic solvent is a polyol, preferably propylene glycol.

5. The composition of the water-based according to claim 1, containing no surfactant.

6. The composition of the water-based according to claim 1, additionally containing dispersible in the E. gelling.

7. The composition of the water-based according to claim 1, optionally containing in addition to benzoyl peroxide is a chemical compound, which is effective in the treatment of acne.

8. The composition of the water-based according to claim 7, characterized in that the chemical compound is soluble in water.

9. The composition of the water-based according to claim 7, characterized in that the chemical compound is an antibiotic, preferably the antibiotic from the group of the macrolide or lincomycin, most preferably clindamycin.

10. A method of obtaining a composition of water-based according to claim 1 for topical use on the skin to treat acne, comprising combining water, miscible with water, an organic solvent and benzoyl peroxide, the concentration of the organic solvent compatible with water and benzoyl peroxide, 1-4 times the concentration of benzoyl peroxide in a specified composition, and the concentration ratio of water and organic solvent, combined in the composition is at least 7:1, preferably at least 10:1, most preferably at least 20:1, and the concentration of benzoyl peroxide, combined in the composition is less than 5.0 wt.%, but at least 1.0 wt.%.

11. The method according to claim 10, characterized in that the concentration of benzoyl peroxide is from 2.0 to 3.5 wt.%.

12. The way the paragraph is paragraph 10, characterized in that the concentration of benzoyl peroxide is about 2.5 wt.%.

13. The method according to claim 10, characterized in that the organic solvent is a polyol, preferably propylene glycol.

14. The method according to claim 10, characterized in that the composition does not include a surfactant.

15. The method according to claim 10, further comprising adding to the composition dispersible in water gel.

16. The method according to claim 10, further comprising adding to the composition in addition to benzoyl peroxide chemical compounds effective in the treatment of acne.

17. The method according to item 16, characterized in that the chemical compound is soluble in water.

18. The method according to item 16, characterized in that the chemical compound is an antibiotic, preferably the antibiotic from the group of the macrolide or lincomycin, most preferably clindamycin.

19. A method of treating acne comprising applying to the affected skin composition for water-based local application on the skin to treat acne according to claim 1, containing water, miscible with water, an organic solvent and benzoyl peroxide,
in which the concentration of organic solvent 1-4 times the concentration of benzoyl peroxide in the composition, and the concentration ratio of water and organic solvent in which the composition is at least 7:1, preferably at least 10:1, most preferably at least 20:1, and the concentration of benzoyl peroxide in the composition is less than 5.0 wt.%, but at least 1.0 wt.%, moreover, the composition is applied for a time sufficient to reduce the signs and/or symptoms of acne.

20. The method according to claim 19, characterized in that the concentration of benzoyl peroxide in the composition is water-based is from 2.0 to 3.5 wt.%.

21. The method according to claim 19, characterized in that the concentration of benzoyl peroxide is about 2.5 wt.%.

22. The method according to claim 19, characterized in. the specified organic solvent is a polyol, preferably propylene glycol.

23. The method according to claim 19, characterized in that the composition is water-based and contains no surfactant.

24. The method according to claim 19, characterized in that the composition additionally contains dispersible in water gelling.

25. The method according to claim 19, wherein the composition in addition to benzoyl peroxide further comprises a chemical compound, which is effective in the treatment of acne.

26. The method according to paragraph 24, characterized in that the chemical compound is soluble in water.

27. The method according to paragraph 24, characterized in that the chemical compound is an antibiotic, preferably the antibiotic from the group of the macrolide or l is of comitini, most preferably clindamycin.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to cosmetology and represents a cosmetic composition containing: hydrolised yeast proteins as an active substance, and at least one acceptable carrier, differing by the fact that the above hydrolised yeast proteins are prepared by exogenic enzymatic hydrolysis and/or acid hydrolysis and/or alkaline hydrolysis of the yeast membranes.

EFFECT: invention provides improved cosmetic activity, excellent time stability.

17 cl, 6 ex, 3 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to dermatology, and may be used for treating the patients suffering acne. That is ensured by local applications of a therapeutically effective amount of a fixed-dose combination containing adapalene and benzoyl peroxide. That is combined with oral administration of a therapeutically effective amount of an antibiotic for a particular period of time.

EFFECT: method provides the effective treatment of these patients, manifested as a significant decrease of all types of acne involvements, prevents the further development of these involvements, including after the withdrawal of oral antibiotics and the development of resistance, due to the synergistic effect of the above local combination and oral antibiotic.

11 cl, 11 tbl, 4 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and cosmetics, more specifically to a topical pharmaceutical composition possessing comedolytic and antibiotic action, comprising an effective amount of the antibiotic clindamycin, salicylic acid and excipients. The pharmaceutical composition is presented in the form of a gel. The excipients are as follows: acrylate copolymer emulsion Salcare SC80, allantoin, antioxidant dihydroquercetin preservative Sharomix MCI, propylene glycol, cyclomethicone DC 345, tocopherol phosphate, UV filter Escalol 567, emulsifier DC 5329, trometamol and thermal water.

EFFECT: stabilised composition has strong comedolytic and antibiotic action, comprises the protective SPF factor which protects inflamed skin against the negative effects of UV radiation and has a shelf life of at least 3 years.

3 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents application of composition, including adapalene and benzoyl peroxide, in preparation of local medication, intended for application by patient who requires it to provide long-term treatment of acne vulgaris, where scheme of application of local medication includes application of therapeutically efficient quantity of composition for, at least, 9 months.

EFFECT: invention ensures achievement of stable positive effect in long-term treatment of acne with composition, including adapalene and benzoyl peroxide, as well as absence of side effects.

19 cl, 1 ex, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of dermatology and represents application of 1-aminoalkylcyclohexane derivative, selected from neramexane and its pharmaceutically acceptable salts for treatment or prevention of inflammatory skin diseases, which represent acne, irritant dermatitis, impetigo and atopic dermatitis.

EFFECT: invention ensures extension of arsenal of medications for treatment of inflammatory skin diseases.

39 cl, 7 ex, 35 tbl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to dermatology, more specifically to methods of treating pyoinflammatory skin diseases, particularly furunculosis and acne. The method of treating the patients suffering pustular skin disorders, according to the invention, consists in the fact that the affected and surrounding skin areas are prepared with warm weak antiseptic, dried and further processed with an ointment prepared by thorough mixing on a water bath until smooth: zinc-salicylic paste, Lorinden C, gioxizone, streptocide liniment, synthomycin liniment and retinol acetate in the ratio of 3÷1÷1÷1÷0.8÷0.1 with skin treatment produced 2 times a day. The weak antiseptic is sodium bicarbonate or chamomile infusion at temperature 40-45°C. Besides, water bath temperature is to be 40-50°C, and the ointment is to be prepared is a glass or ceramic container. Face acne requires the affected area to be warmed with a vapour bath before finally applying the ointment. To prevent accidental wipe-out of ointment from the ointment treated skin, it is covered with the napkins attached to healthy skin. To enhance the effect of the ointment applications, the affected skin is exposed to UV lamp and/or sunlight for 10-30 minutes.

EFFECT: method enables faster treatment and prevented the recurrent disease, and also ensures the prevention of side effects and provides outpatient treatment.

6 cl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and dermatology and represents a composition for treating dermatological disorders containing in a physiologically acceptable medium, at least: (i) peroxide benzoyl, (ii) a naphthoic acid derivative specified in 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 6- [3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid and 6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid and (iii) a compound of polyurethane polymer representing a polyol pre-polymer with said naphthoic acid derivative and said benzoyl peroxide being found in the dispersed form in said composition.

EFFECT: invention provides producing a non-irritant stable composition.

25 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, and concerns preparing an agent for treating various dermatopathies: psoriasis, eczema, atopic dermatitis, ulcers incl. trophic and other diseases accompanied by inflammation or skin flaking. According to the first version, the composition contains ethoxylated alcohol, glycerol monostearate, higher fatty alcohols C16-C18 and cocoglycerides, as well as glycerol, olive oil and water. According to the other versions, it contains naphthalan oil or pentoxifylline or urea. All the versions provide a liposomal form of the composition improving healing, soothing and trophic effects.

EFFECT: composition is hypoallergic, easy-to-use.

12 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.

41 cl, 2 dwg, 6 tbl, 76 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating the acne. A standard drug-induced therapy is prescribed. From the first day of treatment, it is added with 10 sessions of subcutaneous puncture of morphological acne elements with an ozone-oxygen mixture with the ozone concentration of 3500 mcg/ml. The sessions are performed every second day. The volume of the injected ozone-oxygen mixture per each puncture makes 0.2 ml to 0,6 ml. Besides, the preparation Imunorix 800 mg is prescribed in the morning and in the evening orally between meals for the first 14 days of the therapy. Then, for the following 14 days, Imunorix is dosed 400 mg according to the previous regimen.

EFFECT: method allows 29% higher clinical effectiveness in severe and moderate acne, including in patients with accompanying cardiovascular pathologies and with aggravated inflammatory diseases, due to lower intensity of inflammation processes and normalised immune status.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents application of composition, including adapalene and benzoyl peroxide, in preparation of local medication, intended for application by patient who requires it to provide long-term treatment of acne vulgaris, where scheme of application of local medication includes application of therapeutically efficient quantity of composition for, at least, 9 months.

EFFECT: invention ensures achievement of stable positive effect in long-term treatment of acne with composition, including adapalene and benzoyl peroxide, as well as absence of side effects.

19 cl, 1 ex, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and dermatology and represents a composition for treating dermatological disorders containing in a physiologically acceptable medium, at least: (i) peroxide benzoyl, (ii) a naphthoic acid derivative specified in 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 6- [3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid and 6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid and (iii) a compound of polyurethane polymer representing a polyol pre-polymer with said naphthoic acid derivative and said benzoyl peroxide being found in the dispersed form in said composition.

EFFECT: invention provides producing a non-irritant stable composition.

25 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of cosmetics and represents composition for treatment of dermatologic disorders characterised by the fact that it has form of cream-gel and contains in physiologically acceptable medium: from 0.0001 to 20% of dispersed benzoyl peroxide, from 0.0001 to 20% of at least one retinoid, at least one lipophilic compound, which contains fatty phase, and from 0.001 to 15% of at least one pH-independent gelling agent.

EFFECT: invention ensures homogeneity, physical and chemical stability of active composition ingredients.

18 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to dermatology and cosmetology, and represents a composition for prevention or treatment of dermatological diseases associated with disturbed cell differentiation and/or proliferation and/or keratinisation, containing at least one retinoid representing adapalene, and dispersed benzoyl peroxide, differing by the fact that it is presented in the form of an emulsion, and in addition to retinoid and benzoyl peroxide it contains at least one hydrophilic phase, at least one fatty phase, at least one emulsifier.

EFFECT: invention provides high stability of the composition.

19 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology. The invention discloses an ophthalmic composition containing ketotifen and a hydrogen peroxide source supplying hydrogen peroxide in the amount approximately from 0.001 to approximately 0.1% (wt %) with pH making 4 to 5.3. What is also disclosed is a method of treating and preventing allergic conjunctivitis with using said composition.

EFFECT: invention provides minimum adverse side effects in treating and preventing conjunctivitis.

16 cl, 4 tbl, 1 ex

FIELD: ophthalmology.

SUBSTANCE: main composition contains: (a) ketotifen fumarate to the concentration in calculation to free ketotifen from approx. 0.01 mas. % to approx. 0.1 mas.%;(b) source of hydrogen peroxide ensuring presence of hydrogen peroxide with trace quantities amounting from approximately 0.001 to approximately 0.1% (mas./vol.); (c) one or several stabilizers of hydrogen peroxide compatible with eyes; (d) hypromellose to the concentration from approximately 0.005 mas% to approximately 0.5 mas.%; and (e) sodium carboxymethyl cellulose to the concentration from approx. 0.005 mas.% to approx 0.5 mas.%. At this the value of composition pH amounts to approximately from 4.0 to 5.3.

EFFECT: invention is a method of treatment and prevention of allergic conjunctivitis which is ensured with application locally in the effective quantity of the mentioned eye composition to person with allergic conjunctivitis or sensitive to it.

13 cl, 15 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology, and can be applied for treatment of acne vulgaris. For this purpose, complex treatment is performed. On the places of appearance of skin rash additionally applied is propolis powder in form of mask with 3% hydrogen peroxide in ratio 2.0 g per 2 ml of peroxide. Treatment course consists of 10 daily procedures.

EFFECT: method is efficient with absence of side effects, as well as simple in application, is not toxic and economically beneficial.

FIELD: medicine.

SUBSTANCE: invention is related to composition containing water-swellable, water-insoluble polymer, mixed hydrophilic polymer and complementary oligomer capable to form hydrogen bridges and electrostatic couplings with said hydrophilic polymer, and a substrate. The invention is also applied to the method for teeth wigthening.

EFFECT: tooth hypersensitisation minimal or not observed.

58 cl, 3 ex

FIELD: medicine, dermatology, pharmacy.

SUBSTANCE: invention relates to a composition containing at least retinoid, dispersed benzoyl peroxide in physiologically acceptable medium and at least one pH-independent gel-forming substance chosen from polyacrylamides, acrylic polymers with hydrophobic chains, modified starches and their mixtures. Also, invention relates to a method for preparing such composition and its using in dermatology for treatment of differentiation and proliferation of cells or keratinization, and to using in treatment of common acnes. Proposed composition shows high effectiveness in treatment of common acnes, erythematosa acnes and folliculitis. The composition shows a homogenous dispersion of both active substances and physical stability, and good chemical stability of retinoid and benzoyl peroxide.

EFFECT: improved and valuable properties of gel.

19 cl, 6 ex

FIELD: medicine, disinfecting and washing agents.

SUBSTANCE: invention relates to agents for disinfecting and washing of medicine articles such as hemodialysis equipment and dialysers. Claimed agent contains citric acid and water.

EFFECT: agent of increased activity and oxidative properties.

3 tbl, 3 ex

FIELD: medicine, stomatology.

SUBSTANCE: for treating one should apply successively 3%-hydrogen peroxide solution followed by 1%-silver nitrate solution. This provides high antiseptic effect in combination with minimal dental dyeing with solver nitrate solution.

EFFECT: higher efficiency.

6 ex, 1 tbl

Up!